HIV incidence is still increasing in the U.S. despite intense efforts to: (i) diagnose HIV infection as early as possible, (ii) engage newly diagnosed individuals into care and (iii) start antiretroviral therapy (ART) for all infected persons. The San Diego Primary Infection Resource Consortium (PIRC) has been tackling the evolving challenges around these issues for twenty years. The PIRC is the largest, most intensively studied and well-characterized cohort of acute and early HIV infected (AEH) individuals in the United States. It has provided essential support to over 325 peer-reviewed original research manuscripts, spanning a wide range of fields, and including many NIH priority areas for HIV research, including: HIV incidence, strategies to improve HIV testing and entry into prevention services, etc. This application represents a renewal of our PIRC R24 (AI106039) with the proposal to continue this highly productive program, supporting the infrastructure needed to identify, characterize, and share clinical and biological data with scientific colleagues whose research objectives rely upon access to these biological samples and data. The proposed R24 renewal application includes a new collaboration between PIRC and the Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) to develop an expanded and synergistic resource to serve biomedical research in the area of AEH. Overall, the PIRC supports: 1) an HIV screening program to detect and stage acute, recent and chronic infection, 2) partner services to identify sexual contacts of newly HIV diagnosed AEH participants (i.e., ?index? subjects), 3) immediate provision of ART, 4) prompt linkage to care, 5) monitoring of ART adherence and continued engagement in care, 6) methods to estimate putative HIV transmission and 6) an AEH biorepository. This entire biorepository and data associated with these well characterized participants are available to qualified investigators, requiring only internal review and approval of a concept proposal. The proposed R24 renewal application will address the following Specific Aims:
Aim 1. Community HIV Testing and Acute and Early HIV (AEH) Infection Staging. We propose to identify 120 newly HIV diagnosed persons per year at the University of California San Diego: 47 AEH infected and 73 chronically infected participants.
Aim 2. Improve Continuum of HIV Prevention and Treatment. We will evaluate temporal changes in the HIV treatment cascade in response to coordinated efforts to support immediate ART in newly HIV diagnosed PIRC participants. Subjects identified during AEH will be followed for up to 5 years, while chronically infected subjects will be followed in clinic for up to 90 days.
Aim 3. Shared Resources. We will leverage AEH specimen and participant resources to support additional NIH research collaborations related to primary HIV infection. Co-enrollment of AEH participants in CNICS will leverage the clinical monitoring of validated outcomes and longitudinal resistance data provided by CNICS. The PIRC will serve as a resource to support high quality basic, clinical and translational research related to AEH.

Public Health Relevance

The San Diego Primary Infection Resource Consortium (PIRC) is the largest, most intensively studied and well-characterized cohort of acute and early HIV infected individuals in the United States. This infrastructure program supports recruitment, characterization, biological specimen banking and longitudinal follow-up of persons identified during the earliest stages of HIV infection. The proposed PIRC renewal application will ensure that these critical resources are available to scientific colleagues whose research objectives rely upon access to these biological samples and data from these very difficult to find individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Resource-Related Research Projects (R24)
Project #
2R24AI106039-05
Application #
9348986
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Mckaig, Rosemary G
Project Start
2013-08-20
Project End
2022-03-31
Budget Start
2017-08-22
Budget End
2018-07-31
Support Year
5
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Heldt, Sven; Prattes, Juergen; Eigl, Susanne et al. (2018) Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Infect 77:235-241
Stecher, Melanie; Hoenigl, Martin; Eis-Hübinger, Anna Maria et al. (2018) Hotspots of Transmission Driving the Local Hiv Epidemic in the Cologne-Bonn Region, Germany. Clin Infect Dis :
Lin, Timothy C; Dijkstra, Maartje; De Bree, Godelieve J et al. (2018) Brief Report: The Amsterdam Symptom and Risk-Based Score Predicts for Acute HIV Infection in Men Who Have Sex With Men in San Diego. J Acquir Immune Defic Syndr 79:e52-e55
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Sadanand, Saheli; Das, Jishnu; Chung, Amy W et al. (2018) Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors. AIDS 32:443-450
Jenks, Jeffrey D; Hoenigl, Martin (2018) Treatment of Aspergillosis. J Fungi (Basel) 4:
Lin, Timothy C; Burton, Brittany N; Barleben, Andrew et al. (2018) Association of HIV infection with age and symptomatic carotid atherosclerotic disease at the time of carotid intervention in the United States. Vasc Med 23:467-475
Jenks, Jeffrey Daniel; Hoenigl, Martin (2018) CD4:CD8 ratio and CD8+ cell count for prognosticating mortality in HIV-infected patients on antiretroviral therapy. J Lab Precis Med 3:
Hoenigl, Martin; Jain, Sonia; Moore, David et al. (2018) Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1. Emerg Infect Dis 24:
Stecher, M; Chaillon, A; Eis-Hübinger, A M et al. (2018) Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. Clin Microbiol Infect :

Showing the most recent 10 out of 153 publications